Repare Therapeutics RPTX Stock
Repare Therapeutics Price Chart
Repare Therapeutics RPTX Financial and Trading Overview
| Repare Therapeutics stock price | 3.65 USD |
| Previous Close | 12.18 USD |
| Open | 12.18 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 1000 |
| Day's Range | 12.1 - 12.53 USD |
| 52 Week Range | 8.53 - 18.68 USD |
| Volume | 59.9K USD |
| Avg. Volume | 102.88K USD |
| Market Cap | 519.79M USD |
| Beta (5Y Monthly) | 0.057014 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.33 USD |
RPTX Valuation Measures
| Enterprise Value | 203.55M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.7424245 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.791333 |
| Price/Book (mrq) | 2.0683303 |
| Enterprise Value/Revenue | 1.485 |
| Enterprise Value/EBITDA | -11.471 |
Trading Information
Repare Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.057014 |
| 52-Week Change | -6.93% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 18.68 USD |
| 52 Week Low | 8.53 USD |
| 50-Day Moving Average | 10.11 USD |
| 200-Day Moving Average | 12.31 USD |
RPTX Share Statistics
| Avg. Volume (3 month) | 102.88K USD |
| Avg. Daily Volume (10-Days) | 124.25K USD |
| Shares Outstanding | 42.09M |
| Float | 16.63M |
| Short Ratio | 13.54 |
| % Held by Insiders | 6.19% |
| % Held by Institutions | 89.35% |
| Shares Short | 1.26M |
| Short % of Float | 5.07% |
| Short % of Shares Outstanding | 3.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -21.32% |
| Operating Margin (ttm) | -14.33% |
| Gross Margin | 10.94% |
| EBITDA Margin | -12.94% |
Management Effectiveness
| Return on Assets (ttm) | -3.64% |
| Return on Equity (ttm) | -11.46% |
Income Statement
| Revenue (ttm) | 137.1M USD |
| Revenue Per Share (ttm) | 3.27 USD |
| Quarterly Revenue Growth (yoy) | 1291.70% |
| Gross Profit (ttm) | 15.11M USD |
| EBITDA | -17745000 USD |
| Net Income Avi to Common (ttm) | -29231000 USD |
| Diluted EPS (ttm) | -0.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 314.12M USD |
| Total Cash Per Share (mrq) | 7.46 USD |
| Total Debt (mrq) | 5.04M USD |
| Total Debt/Equity (mrq) | 2.01 USD |
| Current Ratio (mrq) | 4.022 |
| Book Value Per Share (mrq) | 5.971 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1458000 USD |
| Levered Free Cash Flow (ttm) | 52.65M USD |
Profile of Repare Therapeutics
| Country | United States |
| State | QC |
| City | St-Laurent |
| Address | 7210 Frederick-Banting |
| ZIP | H4S 2A1 |
| Phone | 857 412 7018 |
| Website | https://www.reparerx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 180 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
Q&A For Repare Therapeutics Stock
What is a current RPTX stock price?
Repare Therapeutics RPTX stock price today per share is 3.65 USD.
How to purchase Repare Therapeutics stock?
You can buy RPTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Repare Therapeutics?
The stock symbol or ticker of Repare Therapeutics is RPTX.
Which industry does the Repare Therapeutics company belong to?
The Repare Therapeutics industry is Biotechnology.
How many shares does Repare Therapeutics have in circulation?
The max supply of Repare Therapeutics shares is 42.18M.
What is Repare Therapeutics Price to Earnings Ratio (PE Ratio)?
Repare Therapeutics PE Ratio is now.
What was Repare Therapeutics earnings per share over the trailing 12 months (TTM)?
Repare Therapeutics EPS is -2.23 USD over the trailing 12 months.
Which sector does the Repare Therapeutics company belong to?
The Repare Therapeutics sector is Healthcare.
Repare Therapeutics RPTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}